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Abstract: Occipital horn syndrome (OHS) is a rare connective tissue disorder caused by pathogenic
variants in ATP7A, encoding a copper transporter. The main clinical features, including cutis laxa,
bony exostoses, and bladder diverticula are attributed to a decreased activity of lysyl oxidase (LOX),
a cupro-enzyme involved in collagen crosslinking. The absence of large case series and natural history
studies precludes efficient diagnosis and management of OHS patients. This study describes the
clinical and molecular characteristics of two new patients and 32 patients previously reported in
the literature. We report on the need for long-term specialized care and follow-up, in which MR
angiography, echocardiography and spirometry should be incorporated into standard follow-up
guidelines for OHS patients, next to neurodevelopmental, orthopedic and urological follow-up.
Furthermore, we report on ultrastructural abnormalities including increased collagen diameter,
mild elastic fiber abnormalities and multiple autophagolysosomes reflecting the role of lysyl oxidase
and defective ATP7A trafficking as pathomechanisms of OHS.
Keywords: occipital horn syndrome; Ehlers–Danlos syndrome type IX; Menkes syndrome; ATP7A;
review; copper transport; elastic fiber; collagen
1. Introduction
Occipital horn syndrome (OHS, OMIM#304150), previously known as Ehlers–Danlos syndrome
type IX or X-linked cutis laxa, is a rare disorder characterized by prominent connective tissue
abnormalities including cutis laxa, hernias, joint laxity and bladder diverticula, and pathognomonic
exostoses with “occipital horns” or downward pointing exostoses situated in the tendinous insertions
of the sternocleidomastoid and trapezius muscles. In addition, patients may show mild to moderate
intellectual disability [1–6]. Being allelic with Menkes disease (MD, OMIM#30011), OHS is considered
the milder end of the phenotypic spectrum due to pathogenic variants in ATP7A [4] that encodes
a copper transporter. Several clinical features in both disorders are related to the malfunctioning
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of cupro-enzymes, including lysyl oxidase, dopamine ß-hydroxylase, tyrosinase and cytochrome C
oxidase [7–10].
ATP7A mediates (1) copper transport from the gastrointestinal tract into the bloodstream,
(2) intracellular delivery of copper to cupro-enzymes in the secretory pathway and (3) efflux of excess
copper from the cell [11,12]. Intracellular ATP7A trafficking is essential for copper homeostasis.
Under basal low copper conditions, ATP7A is found in the trans-Golgi network, where it is essential
for cupro-enzyme biogenesis. At higher copper concentrations, it reversibly localizes to the plasma
membrane and post-Golgi compartments, where it is responsible for the extrusion of excess copper
from the cell [13–15]. The ATP7A gene maps to Xq13.3 and spans a genomic region of ~140 kb.
Its predominant transcription product contains 23 exons [16–20]. ATP7A belongs to the large P-type
ATPase family, which are ATP-driven membrane pumps essential in the maintenance of electrochemical
gradients (such as Na+/K+-, H+/K+- and Ca2+-pumps), as well as lipid and cationic homeostasis [21],
including ATP7A and ATP7B, both important for copper homeostasis [13,22]. P-type ATPases share
a structural core containing a transmembrane (TM) domain responsible for transport and an N-,
P- and A- soluble catalytic domain, respectively involved in nucleotide binding, phosphorylation and
dephosphorylation [23]. The transmembrane domain of ATP7A contains eight transmembrane helices
(TM1–TM8). Six amino terminal domains contain metal-binding CXXC motifs (MBD1–MBD6) [24,25].
MD is mostly caused by truncating variants, including nonsense variants, frameshift variants and
splice-site variants that lead to out of frame transcripts and large deletions, which result in very low
to absent ATP7A levels [12,26]. On the contrary, the milder symptoms in OHS are the consequence
of pathogenic variants in ATP7A, mostly “leaky” splice-site variants resulting in exon-skipping,
which permit the production of a small amount of normal ATP7A mRNA [6,13,27–30]. This low
amount of normal mRNA can result in residual protein activity and allow effective cation transfer to
some copper-dependent enzymes. ATP7A levels as low as 2–5% have been shown to be sufficient to
result in the milder OHS phenotype [31]. Connective tissue abnormalities in OHS have been attributed
to a decreased activity of lysyl oxidase (LOX), a cupro-enzyme that normally deaminates lysine and
hydrolysine residues in the first step of collagen crosslinking [7,32]. Patients may also encounter mild
neurological signs and dysautonomia due to partial defects in dopamine-ß-hydroxylase enzyme activity,
that converts dopamine to norepinephrine, a crucial neurotransmitter in norepinephrinergic neurons.
As such, patients with OHS typically have low to normal levels of serum copper and ceruloplasmin
together with abnormal plasma and cerebrospinal fluid (CSF) catecholamine levels [3,33,34].
Due to the rarity of OHS and the limited number of cases scattered in literature, the natural
history and clinical phenotype remain incompletely studied. This study reports the clinical, molecular
and ultrastructural data for two new cases of OHS. In addition, we performed a clinical review of 32
previously described patients [6,7,11,27–31,35–51].
2. Materials and Methods
2.1. Patients
Informed consent was obtained from subject 1 and his parents, and from subject 2. Additional
consent was given to publish the clinical pictures in Figure 1. Clinical information was obtained by
evaluating both patients at our center with the use of a detailed clinical checklist. We performed
a literature review of 32 OHS patients with confirmed ATP7A pathogenic variants in the Pubmed
and Embase databases, only including studies with ample clinical data. Selection of the reports was
undertaken independently by two different authors (A.B and K.V.M). Clinical data from the literature
were evaluated using the same methodology (Supplementary Table S1). This study was conducted in
accordance with the Declaration of Helsinki and approved by the Ghent University Hospital ethics
committee (registration number B670201319316).
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2.1.1. Clinical Reports
Case 1
Subject 1 (F1:II-1) was born at term after an uncomplicated pregnancy. At birth, his weight
was 2400 g, length 45.5 cm and head circumference 32.4 cm. Developmental milestones were
achieved normally. At three years of age, he presented with micturition problems evolving to urinary
retention, which led to the discovery of giant bladder diverticula. Over subsequent years, several
diverticulectomies were performed, followed by continent diversion and intermittent catheterization.
Clinical examination at 11 years of age showed mild facial dysmorphism (Figure 1) with a flat face,
deep-set eyes, a long narrow nose, large ears and mild webbing of the neck. His weight was 24.9 kg (P1,
−2.37 SD), height 139.2 cm (P26, −0.649 SD) and head circumference 56.2 cm (P98, +2.1 SD). Skeletal
abnormalities included joint hyperlaxity of the wrists, metacarpophalangeal joints and fingers, a flat
back, marked bony thickening of the proximal radius and tibia, genua valga and pedes plani. There was
skin webbing between the second and third toe. His skin was soft and mildly hyperextensible with fine
wrinkles over the abdomen and dorsum of hands and feet. He had no hair abnormalities. Neurological
examination was normal. He had recurrent inguinal hernias. He reported bruising easily, but no
impaired wound healing. He suffered from chronic joint pain. The patient attended normal education.
Additional examinations included a total skeletal radiography and MRI/MRA (Figure 2).
X-rays show severe skeletal dysplasia, occipital horns, undertubulation of bony structures and
broadening of the ventral end of the first left rib, the distal end of both claviculae and the scapular
neck. The long bones showed bowing with mid-diaphyseal broadening. There was bilateral luxation
of the radial heads, bilateral overgrowth of the ulnar coronoid processes and prominent trochanter
minor of both femurs. We observed a short fibula and bilateral coxa valga with rounded iliac wings.
The metatarsals were broad. The vertebrae showed platyspondyly. Brain MRI and angiography
showed tortuous intracranial arteries. Echocardiography, lung radiography and spirometry were
normal. Serum copper and ceruloplasmin levels were within normal ranges (89.6µg/dL (70–140) and
0.287 g/L (0.2–0.6), respectively).
Figure 1. Clinical characteristics in subjects F1:II-1 and F2:II-1. Subject F1:II-1 displays mild facial
dysmorphism with a flat face, deep-set eyes, a long and narrow nose, large ears and mild webbing
of the neck. Craniofacial features in patient F2:II-1 are more pronounced and include dolichocephaly,
a high forehead, biparietal narrowing, downslanting eyes, a convex nasal ridge, midfacial hypoplasia,
micrognathia and low-set ears. No hair abnormalities were observed. Both have lax and hyperextensible
skin, marked joint hypermobility and deformities of the proximal radius.
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Figure 2. Total skeletal radiography and MRI/MRA studies in subject F1:II-1 showing severe skeletal
dysplasia with occipital horns, undertubulation of bony structures and broadening of the ventral end
of the first left rib, both claviculae and scapular neck, bowing of the long bones with mid-diaphyseal
broadening, bilateral luxation of the radial heads, bilateral overgrowth of the ulnar coronoid processes,
prominent trochanter minor of both femurs, short fibula, bilateral coxa valga with rounded iliac wings
and broad metatarsals. Brain MRI and angiography showed tortuous intracranial arteries and normal
brain structure.
Case 2
Subject 2 (F2:II-1) was evaluated at the age of 30. He was born at term after an uncomplicated
pregnancy. He developed an inguinal hernia at six weeks of age. Since then, he had multiple inguinal
and femoral hernias requiring repeated mesh repairs. Starting from two years of age, he had severe
bladder problems, including recurrent urinary tract infections and urinary retention, due to multiple
bladder diverticula. After more than 20 surgical bladder repairs, he started self-catheterization at 8
years of age. Aged 20 years, he underwent left nephrectomy for a non-functioning kidney. He reported
a mild motor delay and walked at two years of age. Joint hypermobility resulted in repeated shoulder
and elbow subluxations. He was of normal intelligence and pursued higher education. He suffered
from migraine, worsening musculoskeletal pain, fatigue, and depression for which he was treated
with gabapentin and amitriptyline. He had a history of mitral valve prolapse, orthostatic hypotension,
palpitations and a prolonged QT interval on electrocardiogram. Finally, he had a longstanding history
of upper and lower gastrointestinal symptoms including nausea, post-prandial vomiting and chronic
diarrhea, possibly in the context of dysautonomia. He was diagnosed with asthma.
His height was 169 cm, his weight was 50.6 kg and his head circumference was 58.5 cm. Craniofacial
features consisted of dolichocephaly, a high forehead, biparietal narrowing, downslanting eyes, a convex
nasal ridge, midfacial hypoplasia, micrognathia and low-set ears. He had lax and hyperextensible skin
(Figure 1). He had no hair abnormalities. Skeletal abnormalities included occipital horns, a loss of
sagittal spine curvature, scoliosis, pectus excavatum, and restricted elbow extension. He had bowing
of the ulna and radius, bilateral exostoses of the radii and tibiae, bilateral rounding of the iliac wings,
cranial displacement of the right humeral head and genua vara. Neurological examination and brain
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MRI were normal. Serum copper and ceruloplasmin levels were 8.3 µmol/L (11–20) and 0.13 g/L
(0.20–0.50), respectively.
2.2. Molecular Analysis
For individual 1, genomic DNA was extracted from blood leukocytes using standard
procedures. Array comparative genomic hybridization (180 k arrayCGH, Agilent
Technologies, Santa Clara, CA, USA) showed a 300 kb deletion of chromosome band 1q31.1
(1q31.1.1q31.1(188407205-188707983)x1)(hg19/GRCh37), which does not contain any known genes.
FBLN5 (OMIM#219100, GenBank RefSeq accession number NM_006329.3), LTBP4 (OMIM#613177,
NM_003573.2) and ATP7A (OMIM#304150, NM_000052.7) gene sequencing was performed without the
identification of a pathogenic mutation. Total RNA was extracted from cultured fibroblasts using the
RNeasy Kit (Qiagen, Hilden, Germany) and cDNA was synthesized with the iScript cDNA Synthesis
Kit (Bio-Rad Laboratories, Hercules, CA, USA). ATP7A cDNA analysis was performed followed by
confirmation with long-range RT-PCR and next-generation sequencing (Miseq, Illumina, San Diego,
CA, USA). For individual 2, array comparative genome hybridization was normal after which ATP7A
gene sequencing (GenBank RefSeq accession number NM_000052.7) was performed.
2.3. Transmission Electron Microscopy (TEM)
For transmission electron microscopy, 3 mm skin fragments from both individuals and an age- and
sex-matched control were immersed in a fixative solution of 2.5% glutaraldehyde and 4% formaldehyde
in Na-Cacodylate buffer 0.1 M, placed in a vacuum oven for 30 min and left rotating for 3 hours at
room temperature. This solution was later replaced with fresh fixative and samples were left rotating
over night at 4 ◦C. After washing, samples were post-fixed in 1% OsO4 with K3Fe(CN)6 in 0.1 M
NaCacodylate buffer, pH 7.2. After washing in double-distilled H2O, samples were subsequently
dehydrated through a graded ethanol series, including bulk staining with 2% uranyl acetate at the 50%
ethanol step, followed by embedding in Spurr’s resin. To select the area of interest on the block and in
order to have an overview of the phenotype, semi-thin sections were first cut at 0.5 µm and stained
with toluidine blue. Ultrathin sections of a gold interference color were cut using an ultramicrotome
(Leica EM UC6, Wetzlar, Germany), followed by post-staining in a Leica EM AC20 for 40 min in uranyl
acetate at 20 ◦C and for 10 min in lead stain at 20 ◦C. Sections were collected on formvar-coated copper
slot grids. Grids were viewed with a JEM 1400plus transmission electron microscope (JEOL, Tokyo,
Japan) operating at 80 kV.
2.4. Collagen Biochemical Analysis
Fibroblast cultures were started from skin biopsies from individuals 1 and 2, and a matched control.
Biochemical (pro)collagen sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE
analysis) was performed on the medium and cellular fractions of the cultured skin fibroblasts.
When confluent, cells were labeled with 14C-proline [52]. After SDS-PAGE separation, further
processing of the gels was performed as described previously by our group [53].
3. Results
3.1. Clinical Characteristics
We describe the clinical characteristics of two new individuals with OHS and 32 patients described
in the literature (Table 1, Supplementary Table S1). All patients were male, except for patient F17:II-2.
The mean reported age of patients was 19.6 years (mean 17, range 1–50). Disease-related mortality was
observed in 5 out of 34 patients. The mean age at death was 21.2 years and causes included respiratory
failure (post-surgery apnea), gastric perforation and diffuse intravascular coagulation due to a large
cephalhematoma at birth.
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Table 1. Overview of the phenotypic presentation in occipital horn syndrome.
Total (Percentage)
Craniofacial
Long face 6/13 (46%)
Large ears 5/13 (38%)
Sagging/ full cheeks 5/11 (45%)
Hair abnormalities 14/19 (74%)
Pili torti on trichoscopy 7/10 (70%)
Connective tissue
Cutis laxa 25/27 (93%)
Inguinal hernia 15/24 (63%)
Umbilical hernia 1/22 (5%)
Osteoarticular
Occipital horns 25/26 (96%)
Radial/tibial exostoses 6/16 (38%)
Hammer-shaped clavicula 9/19 (47%)
Bowing of long bones 4/17 (23%)
Mid-diaphyseal broadening 2/17 (11%)
Rounding of the iliac wings 3/17 (18%)
Coxa valga 6/16 (38%)
Genu valgum 6/17 (35%)
Metaphyseal spurring 2/16 (13%)
Scoliosis 8/21 (38%)
Pectus deformity 13/23 (57%)
Dislocations 12/20 (60%)
Contractures of large joints 3/19 (16%)
Joint hyperlaxity 16/26 (62%)
Fractures 2/21 (10%)
Neurological
Intellectual disability 17/33 (52%)
Seizures 5/25 (20%)
Muscle hypotonia 10/25 (40%)
Stroke 1/23 (4%)
Cardiovascular
Aneurysm formation 5/7 (71%)
Dilatation of the large veins 2/6 (33%)
Intracranial tortuosity 7/11 (64%)
Extracranial tortuosity 3/4 (75%)
Dysautonomia 13/15 (87%)
Urogenital
Bladder diverticula 25/30 (83%)
Renal abnormalities 6/20 (30%)
Urinary tract infections 17/23 (74%)
Vesicourethral reflux 7/23 (30%)
Laboratory findings
Serum copper 20/28 (71%)
Serum ceruloplasmin 20/27 (74%)
Initial presentations leading to the diagnosis are presented in Table 2. One-third of patients
presented with neurological features including hypotonia, developmental delay, and seizures.
Nine individuals presented with connective tissue problems such as cephalhematoma and inguinal
hernia. Other presenting symptoms included bladder problems such as bladder diverticula, urinary
tract infections and skeletal problems.
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Table 2. Initial presentations leading to the diagnosis in occipital horn syndrome.






















“CTD”: connective tissue disease.
Patients displayed variable craniofacial features, including a long face (6/13, 46%), large ears
(5/13, 38%), sagging cheeks (5/11, 45%) and hair abnormalities (14/19, 74%). Trichoscopy confirmed
pili torti in 7 out of 10 examined individuals. Connective tissue abnormalities were reported in
all subjects. Cutis laxa was present in the majority of patients (25/26, 94%), as well as inguinal
hernias (15/25, 63%). An umbilical hernia and hiatal hernia were observed in only one patient each
(F25:II-1 and F15:II-1, respectively). Wound healing was reported to be normal after trauma or surgery.
Occipital horns were reported in nearly all cases (25/26, 96%). Other recurrent skeletal manifestations
included hammer-shaped claviculae (9/19, 47%), scoliosis (8/21, 38%), pectus deformities (13/23, 57%),
radial/tibial exostoses (6/16, 38%), coxa valga (6/16, 38%) and genua valga (6/17, 35%). Dislocations,
mainly of the radial heads and joint hypermobility were present in about two-thirds of individuals,
12/20 (60%) and 16/26 (62%), respectively. Less frequently reported skeletal manifestations include
bowing of the long bones, mid-diaphyseal broadening, metaphyseal spurring and rounding of the
iliac wings. Osteopenia or osteoporosis was reported in four patients and fractures were observed in
two subjects.
Mild, mainly motor, developmental delay, was observed in 17 subjects (17/30, 57%). Intellectual
disability was present in an equal number of patients (17/33, 52%) of whom seven had mild, four had
moderate and three had severe intellectual disability. In three patients, the severity of intellectual
disability was not specified. Several subjects displayed muscle hypotonia, especially at a young age
(before the age of two). Seizures were documented in five patients (5/25, 20%). One individual was
diagnosed with a spontaneous intracerebral hemorrhage at the age of 15, resulting in aphasia and
spastic quadriparesis. MRI brain studies were performed in 11 patients and documented to be abnormal
in 7 subjects, showing mild atrophy and/or delayed myelination. Intracranial tortuosity was present in
two-thirds of patients (7/11, 64%). Tortuosity of extracranial arteries was found in three cases and was
located in the cervical, splenic and hepatic arteries. Aneurysm formation was found in five patients,
mainly affecting the same arteries. One individual was diagnosed with a type A aortic dissection
at the age of 39, which was successfully surgically manage. Two patients showed dilatation of the
large veins. Orthostatic hypotension, temperature instability, chronic diarrhea, and other symptoms of
dysautonomia were seen in a high number of patients (13/15, 87%). Severe urological complications are
an important concern in OHS, with bladder diverticula in 83% (25/30) of reported patients, of which
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three were eventually diagnosed with a bladder rupture. Recurrent urinary tract infections based
on incomplete emptying of the bladder were seen in 74% (17/23) of patients. One-third of patients
had vesicourethral reflux (VUR), sometimes complicated by secondary renal problems. Asthma was
reported in four cases. Low levels of serum copper and ceruloplasmin were found in two-thirds of
cases, 20/28 (71%) and 20/27 (74%), respectively.
3.2. Molecular Characteristics
After normal ATP7A gene sequencing, cDNA analysis showed a deletion of exon 10 in subject
F1:II-1. Subsequent confirmation with long-range RT-PCR revealed a deep intronic c.2407-516G>T
variant, underlying the exon 10 skipping, likely due to the activation of a cryptic splice acceptor.
In patient F2:II-1, ATP7A gene sequencing identified a hemizygous c.2917-4A>G splice-site variant
in ATP7A.
A total of 16 different ATP7A pathogenic variants were reported (Figure 3); these included seven
splice-site, four missense and two frameshift variants, two deep intronic variants and one deletion.
In eight patients, the specific variant was not reported, including a 98-bp deletion in the regulatory
region (F9:II-1), a deep intronic intron six splice donor site variant (F12:II-1) and a duplication in exon 11
and 12 (F23:II-1). Nonsense ATP7A variants were not observed. Pathogenicity information and CADD
scores can be found in Supplementary Table S2. We did not observe any clear genotype-phenotype
correlation and there was no correlation with serum copper and ceruloplasmin levels (Supplementary
Table S3).
Figure 3. ATP7A pathogenic variants reported in this study. ATP7A consists of six amino terminal
metal binding domains (MBD1-MBD6), a transmembrane domain containing eight transmembrane
helices (TM1-TM8) and an N-, P- and A- soluble catalytic domain. The pathogenic variants identified
in subjects F1:II-1 and F2:II-1 are indicated in bold and outlined.
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3.3. Transmission Electron Microscopy
Transmission electron microscopy (TEM) findings in skin samples of subjects F1:II-1, F2:II-1 and
a matched control are shown in Figure 4. Collagen fibrils in the dermis of the control sample are
regularly organized in curvilinear bundles with uniform diameters. In the dermis of both OHS patients,
the collagen fiber diameter appears to be larger and more variable. The fibrils are more loosely packed
(especially in F2:II-1) but retain a normal shape. TEM of a control elastic fiber demonstrates a solid and
dense core of elastin surrounded by a sparse mantle of microfibrils. In both individuals, the elastin core
is surrounded by a debris extending outside the elastic fiber with loss of the microfibrillar organization.
In addition, the elastin core in subject F2:II-1 is almost completely disrupted and difficult to discriminate.
Fibroblast abnormalities are observed in both patients, with multiple autophagolysomes containing
sickle-shaped electron dense deposits (Supplementary Figure S1). The mitochondria, Golgi complex,
and endoplasmatic reticulum appear normal.
Figure 4. Transmission electron microscopy findings in occipital horn syndrome. Transmission electron
microscopy (TEM) findings in skin samples of patients F1:II-1 and F2:II-1 and a matched control showing
collagen (column 1), elastic fibers (column 2) and a fibroblast (column 3). col = collagen; ef = elastic
fiber; fb = fibroblast. Magnification for column 1: ×15,000, column 2: ×8000 and column 3: ×4000.
3.4. Collagen Biochemistry
Considering the collagen abnormalities observed in both individuals with transmission electron
microscopy, SDS-PAGE analysis of the intracellular and secreted (pro)collagen proteins produced by
skin fibroblasts was performed for subjects 1 and 2 and a matched control. In both cases, we observed
normal SDS-PAGE migration patterns (Supplementary Figure S2).
4. Discussion and Conclusions
The absence of large case series and natural history studies precludes efficient diagnosis and
management of OHS patients. This study describes the clinical and molecular characteristics of two
new patients and 32 patients previously reported in the literature. OHS is considered a mild but rare
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allelic variant of Menkes disease. OHS patients show prominent connective tissue abnormalities and
have a better prognosis and survival rate than patients with MD [3], with low childhood mortality (1/34)
in OHS. However, there is still significant mortality in (young) adults, often related to gastrointestinal,
respiratory, or bleeding complications, such as an intestinal perforation due to a gastric ulcer and
(post-surgery) apnea.
The clinical characteristics of OHS are listed in Table 2. Craniofacial features include mild facial
dysmorphism with a long face, large ears and sagging cheeks in about half of reported patients.
Hair abnormalities, including coarse hair and pili torti, are frequently present. Ubiquitous connective
tissue manifestations in OHS include increased skin laxity and inguinal hernia.
Concerning the skeletal features, the pathognomonic occipital horns are present in all patients
but one, which is probably an age-dependent discrepancy [41,54,55]. Other less specific skeletal
abnormalities include hammer-shaped claviculae and radial/tibial exostoses. Scoliosis, pectus
deformities, coxa and genua valga, joint luxations, mainly of the radial heads and general joint
hypermobility are frequent but non-specific. These skeletal problems may limit daily activities and
often require multiple surgical interventions.
Urological complications, mostly giant bladder diverticula and vesicourethal reflux, are found in
over 80% of subjects. Secondary problems such urinary tract infections, urinary retention, bladder
rupture, or VUR-mediated renal failure, which are all related to the bladder diverticula, are of great
concern. Surgical interventions removing the diverticula often fail, with frequent relapse of the
diverticula. Self-catheterization, vesicostomy, or continent diversion are often required for proper
emptying of the bladder.
Previous reports describe a mild neurological phenotype limited to slight generalized muscle
weakness and symptoms of dysautonomia [3,27], however, more detailed case studies reveal some
conspicuous observations including developmental delay and intellectual disability in two-thirds of
subjects and documented seizures in five individuals. Nevertheless, neurological affliction remains
rather mild and normal intelligence is possible. Symptoms of dysautonomia, including chronic
diarrhea, temperature instability, and orthostatic hypotension are present in almost 90% of patients
and can be disabling.
Brain imaging studies are rarely performed in OHS patients and are often reported as normal.
However, intracranial arterial tortuosity are noted in approximately two thirds of patients. Extracranial
arterial tortuosity is less frequently observed, but has been reported in the cervical, splenic and hepatic
vasculature. Aneurysm formation may complicate pre-existing tortuosity and may affect the arterial
and venous circulation.
OHS is often diagnosed upon the identification of connective tissue anomalies, including cutis laxa,
joint hypermobility with hypotonia, mild intellectual impairment and bladder diverticula. Later on,
the pathognomonic occipital horns become more evident. The initial differential diagnosis includes other
forms of cutis laxa, including FBLN5- and LTBP4-related cutis laxa (OMIM#219100 and #613177) [56] and
the dermatosparaxis type of Ehlers–Danlos syndrome (EDS type VIIC, OMIM#225410) [57], which may
present with cutis laxa, hypotonia and bladder diverticula, but with normal mental development.
However, in OHS there is no early onset emphysema as in FBLN5- and LTBP4- related cutis laxa,
nor easy bruising or severe skin fragility as in the dermatosparaxis type of EDS. ATP6V0A2-related
cutis laxa (OMIM#219200) may also present with mild intellectual impairment but does not commonly
show bladder diverticula or exostoses. Later on the exostoses can be mistaken for hereditary multiple
exostoses due to defects in EXT1 or EXT2 (OMIM#133700 and #133701) [58].
Concerning follow-up, routine evaluation of neurodevelopment and early intervention with
physiotherapy is recommended, as well as regular urological evaluation, including video urodynamic
studies of bladder function. Any pain, or vascular or neurological symptoms that may relate to exostoses
should be promptly investigated. To date, there are no data on a possible risk for chondrosarcomas
in exostoses although these have been described in hereditary multiple exostoses [59]. It could be
recommended to perform MR angiography and echocardiography from puberty onwards. Indeed,
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aortic root dilatation and dissection, and an increased risk for intracranial bleeds and ischemic
complications have been described in other related connective tissue disorders such as Ehlers–Danlos,
arterial tortuosity, Marfan and some cutis laxa syndromes. Furthermore, spirometry might detect
asthma at an early stage as it was reported in four individuals. Prolonged vigilance for apnea is
necessary following surgery.
The molecular data confirmed that pathogenic variants in ATP7A causing OHS mainly
included splice-site variants, while missense and frameshift variants were less frequently observed.
This observation may fit the hypothesis that a low amount of normal ATP7A mRNA and residual
ATP7A functioning is sufficient to prevent the more severe MD [13,27,29,31,60]. No mutational hot
spots were observed (Figure 3). Importantly, nearly all pathogenic variants are located in the endofacial
domains and only two affect a transmembrane domain or cytosolic loop, respectively. This highlights
the critical role of the transmembrane domains forming the channel for copper translocation [13].
Variants in OHS mainly affect residues implicated in ATPase-coupled copper transport. Some of these
variants are predicted to inhibit the catalytic dephosphorylation leading to permanent distribution of
the protein to the plasma membrane and cytosolic vesicles [14,15,21,61,62].
Our transmission electron microscopy data in skin samples of OHS individuals show larger
diameters of collagen fibrils that were more loosely packed compared to those of the control sample.
Elastic fibers were affected to a lesser extent but are fragmented and/or surrounded by extracellular
matrix debris. OHS is associated with decreased activity of the copper dependent lysyl oxidase (LOX),
that oxidates lysyl and hydroxylysyl residues in collagen and lysyl residues in elastin to aldehydes [7].
These aldehyde residues are than condensed to form cross-links, essential for collagen fibril stabilization
and the integrity and elasticity of mature elastin [32,63]. Overall, this would not affect the amount
or migration of soluble collagens from the medium or cellular fraction upon electrophoresis but will
affect the assembly in the extracellular matrix. Also, lysyl oxidase may form cross-links with the
N-propeptide domain of collagen type V, essential in collagen diameter regulation [64,65]. Fibroblasts
synthesize only low amounts of type V collagen which is difficult to evaluate by electrophoresis [66,67].
Indeed, irregular fibril diameters are reminiscent of classic Ehlers–Danlos syndrome, despite the
absence of cauliflower fibrils [68].
The observation of major fibroblast abnormalities, with multiple autophagolysosomes containing
sickle-shaped electron dense deposits, is novel and might point to defective trafficking and trapping of
proteins needing cuproenzyme-dependent processing in the post-Golgi network [14,15,21].
In conclusion, this study sheds light on the natural history of OHS by describing two new patients
and 32 patients reported in the literature. Mortality in adulthood warrants long-term specialized
care and follow-up, incorporating MR angiography, echocardiograpy and spirometry into standard
follow-up guidelines for OHS patients, next to orthopedic and urological follow-up. Ultrastructural
abnormalities including increased collagen diameter, mild elastic fiber abnormalities, and multiple
autophagolysosomes reflect the role of LOX and defective ATP7A trafficking in the pathomechanism
of OHS.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/7/528/s1;
Supplemental Figure S1: Fibroblast abnormalities in OHS. Magnification: x4000, x8000 and x15000; Supplemental
Figure S2: SDS-PAGE collagen analysis in patients F1:II-1 and F2:II-1 and a matched control. Panel A: medium
procollagen fraction on fibroblasts in culture for three days. Panel B: cellular collagen fraction; Supplemental
Table S1. Clinical characteristics of all patients. ‘”+”: present, “-“: absent, “M”: male, “F”: female, “y”:
year(s), “mo”: month(s), “d”:day(s), “CVA”: cerebrovascular accident, “DIC”: diffuse intravascular coagulation,
“FTT”: failure to thrive, “GER”: gastro-esophageal reflux, “SC”: subcutaneous, “UTI”: urinary tract infection;
Supplemental Table S2. Pathogenicity information for the ATP7A variants in this study. The pathogenicity
classification used in this table is based on the Alamut®mutation analysis software, which uses the following
prediction tools: Align GVGD (Huntsman Cancer Institute, University of Utah) combines the biophysical
characteristics of amino acids and protein multiple sequence alignments to where missense substitutions in genes
of interest fall from enriched deleterious to enriched neutral. SIFT predicts whether amino acid substitution
affects protein function. The MutationTaster prediction program integrates information from different biomedical
databases, evolutionary conservation, splice-site changes and loss of protein features. Protein conservation is
based on MARRVEL®multiple protein alignment. The splice prediction predicts the chance of variants having
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an impact on alternative splicing. Gnomad allele frequencies and Clinvar data can also be found. In the last
column, CADD scores are depicted (Kircher et al., 2014). “NS”: not specified, “NA”: not applicable; Supplemental
Table S3. Copper and ceruloplasmin levels in all patients.
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